WallStSmart

Amazon.com Inc (AMZN)vsBrilliA Inc (BRIA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amazon.com Inc generates 1206430% more annual revenue ($742.78B vs $61.56M). AMZN leads profitability with a 12.2% profit margin vs 2.8%. BRIA trades at a lower P/E of 19.0x. AMZN earns a higher WallStSmart Score of 65/100 (C+).

AMZN

Buy

65

out of 100

Grade: C+

Growth: 8.7Profit: 6.5Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.33

BRIA

Avoid

32

out of 100

Grade: F

Growth: 2.0Profit: 5.5Value: 5.3Quality: 8.0
Piotroski: 4/9Altman Z: 5.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMZNSignificantly Overvalued (-60.9%)

Margin of Safety

-60.9%

Fair Value

$152.91

Current Price

$246.03

$93.12 premium

UndervaluedFair: $152.91Overvalued

Intrinsic value data unavailable for BRIA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMZN4 strengths · Avg: 9.3/10
Market CapQuality
$2.65T10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
74.8%10/10

Earnings expanding 74.8% YoY

Return on EquityProfitability
20.6%9/10

Every $100 of equity generates 21 in profit

Revenue GrowthGrowth
16.6%8/10

16.6% revenue growth

BRIA2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.0110/10

Safe zone — low bankruptcy risk

Areas to Watch

AMZN4 concerns · Avg: 3.3/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

P/E RatioValuation
31.7x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Free Cash FlowQuality
$-18.17B2/10

Negative free cash flow — burning cash

BRIA4 concerns · Avg: 2.8/10
Market CapQuality
$38.00M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
2.8%3/10

2.8% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

Revenue GrowthGrowth
-10.3%2/10

Revenue declined 10.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMZN

The strongest argument for AMZN centers on Market Cap, EPS Growth, Return on Equity. Revenue growth of 16.6% demonstrates continued momentum.

Bull Case : BRIA

The strongest argument for BRIA centers on Debt/Equity, Altman Z-Score.

Bear Case : AMZN

The primary concerns for AMZN are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : BRIA

The primary concerns for BRIA are Market Cap, Profit Margin, Operating Margin. Thin 2.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

AMZN profiles as a growth stock while BRIA is a value play — different risk/reward profiles.

AMZN is growing revenue faster at 16.6% — sustainability is the question.

BRIA generates stronger free cash flow (-5M), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMZN scores higher overall (65/100 vs 32/100) and 16.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amazon.com Inc

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Amazon.com, Inc. is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence. It is one of the Big Five companies in the U.S. information technology industry, along with Google, Apple, Microsoft, and Facebook. The company has been referred to as one of the most influential economic and cultural forces in the world, as well as the world's most valuable brand.

Visit Website →

BrilliA Inc

CONSUMER CYCLICAL · APPAREL RETAIL · USA

BrilliA Inc. is an innovative biotechnology company dedicated to enhancing skin health and advancing regenerative medicine through cutting-edge solutions for wound healing. By harnessing proprietary technologies, BrilliA addresses significant unmet medical needs, aiming to improve patient quality of life. With a strong commitment to research and development, the company is well-positioned to transform scientific advancements into effective therapeutic products, solidifying its role as a leader in the dynamic healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?